e-ISSN: Pending
Negative / Null Result ReportOpen accessDiseases of the circulatory (Cardiovascular) system

Oral milrinone for management of refractory right ventricular failure in patients with left ventricular assist devices

Waqas Akhtar; Charles Butcher; Andrew Morley‐Smith; Fernando Riesgo Gil; Owais Dar; Veronica Baston; John Dunning; Haifa Lyster · 2022 · ESC Heart Failure

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Abstract Aims We present a single‐centre retrospective experience using oral milrinone in patients with a left ventricular assist device (LVAD) and concurrent refractory right ventricular failure. Methods and results All patients implanted with LVAD between January 2013 and July 2021 from a high‐volume advanced heart failure service were reviewed. Eight patients were initiated on oral milrinone during this period. Oral milrinone was started 1.5 [inter‐quartile range (IQR) 1–2.3] years after LVAD implantation and continued for 1.2 (IQR 0.5–2.8) years. Therapeutic milrinone levels were achieved

Abstract by Waqas Akhtar; Charles Butcher; Andrew Morley‐Smith; Fernando Riesgo Gil; Owais Dar; Veronica Baston; John Dunning; Haifa Lyster, ESC Heart Failure (2022) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: DOAJ · DOI 10.1002/ehf2.14092